Malignant infantile osteopetrosis (MIOP) is a heterogeneous group of severe disorders characterized by abnormal osteoclast activity. In untreated disease, children typically suffer severe bony abnormalities, hematopoietic failure, cranial neuropathies and death within the first decade. 1 Allogeneic hematopoietic stem cell transplantation (HSCT) can be curative for MIOP, and outcomes following HLAmatched related-donor (MRD) transplant are favorable. In sharp contrast, alternative-donor transplant for MIOP remains plagued by graft failure, regimen-related toxicity and poor overall survival. 2, 3 Related, HLA-haploidentical donor HSCT has again emerged as a promising alternative-donor treatment strategy for patients with hematologic malignancies. Previous iterations of 'haplo-transplant' have generally failed to unify the desired transplant outcomes, including robust donor engraftment, low rates of GvHD and timely immune reconstitution. However, a T-cell replete, nonmyeloablative regimen utilizing post-graft infusion high-dose cyclophosphamide (Haplo-post-transplant cyclophosphamide (PTCy)) has demonstrated efficacy approaching that following MRD HSCT. 4 In addition, emerging reports chronicle success using the Haplo-PTCy platform for aplastic anemia and hemoglobinopathies. [5] [6] [7] We hypothesized that the Haplo-PTCy strategy following reduced-intensity conditioning would achieve long-term engrafted survival for children in need of alternative-donor transplantation for MIOP, a disease in which donor carrier status does not impact the efficacy of transplantation.
Three consecutive children with MIOP, all with recessive TCIRG1 genotypes, presented to our institution without HLA-matched sibling donors and were treated by the Haplo-PTCy strategy in 2014-2015. In all patients, MIOP diagnosis was prompted when abnormal bone mineralization was incidentally seen on imaging for infectious concerns. Severe OP phenotype was evidenced in all children by bone marrow failure requiring transfusion of platelets and/or RBCs. All patients were o1 year old at the time of transplant. All underwent induction within 2 months of their diagnoses. Additional patient characteristics can be seen in Table 1 .
Following the provision of informed parental consent, all patients received uniform reduced-intensity conditioning with four doses of fludarabine and thymoglobulin along with 2 days of dose-adjusted busulfan as outlined in Figure 1 . All patients were rescued with paternal, HLA-haploidentical, T-cell replete and PBSC grafts. No grafts were manipulated. No patients harbored donorspecific anti-HLA antibodies. GvHD prophylaxis consisted of highdose posttransplant cyclophosphamide (PTCy), cyclosporine A and mycophenolate mofetil. Growth factor support through neutrophilic recovery was with sargramostim.
The first patient had a largely unremarkable transplant course with rapid, donor-derived neutrophil, and platelet recovery and minimal treatment-related toxicity. He was successfully treated for uncomplicated Pseudomonas aeruginosa and Staphylococcus epidermidis bloodstream infections. He was noted on PCR-based screening surveillance to have transient adenoviremia and cytomegaloviremia. Both were successfully treated and neither was clinically significant. His absolute peripheral blood CD4 + counts were 177, 253, 672 and 1223/μL at days +42, +60, +100 and +365, respectively; the serum IgG was 743 mg/dL at day +100. He is now 18 months out from Haplo-PTCy and thriving with stable donor engraftment, continued transfusion-independence, no signs of GvHD, preserved vision and hearing, and radiographic improvement of OP.
The subsequent two infants both experienced graft failure. Although patient 2 initially allo-engrafted following paternal Haplo-PTCy, he gradually reverted to autologous hematopoiesis with no evidence of donor engraftment. He underwent a second transplant (183 days following his first) using an HLA-matched, unrelated marrow graft and showed rapid allo-engraftment. Remained aplastic after second HSCT; death from sepsis 1°= primary aplastic graft failure; 2°= secondary graft failure after initial allo-engraftment; ANC/plt = days to neutrophil and platelet (50 000/μL) recovery; BU AUC = actual total regimen busulfan exposure in mg × h × L − 1 ; d = days; donor % = percentage donor contribution to fractionated blood at days 21, 42 and most recent (MR) follow-up or second HSCT, where applicable (if only one number appears, testing was obtained on non-fractionated blood); F = female; Hgb/plt = pretransplant hemoglobin (g/dL) and platelet count (×10 However, he died on day +37 from noninfectious respiratory failure. The third patient experienced slow autologous hematopoietic recovery with no evidence of paternal engraftment following Haplo-PTCy. She was rescued with a stored autologous peripheral blood CD34 + graft on day +41. On day 81 following her initial transplant, she underwent repeat PBSC transplantation using a maternal, T-replete and haploidentical graft (TNC dose of 50.3 × 10 6 /kg; CD3 + dose of 18 × 10 8 /kg). She never experienced hematologic recovery and died 47 days later of overwhelming sepsis.
Recent, large-cohort, multi-center analyses have shown poor engrafted survival for children with MIOP who undergo alternative-donor transplantation. In this setting, the major barriers to treatment success remain excessive regimen-related toxicity and graft failure. 2, 3 Achieving sufficient immune and myeloid ablation for alternative-donor grafting in the MIOP population, which appears especially prone to complications from cytotoxic regimens, remains a vexing challenge. 8, 9 Still, there is great interest in optimizing outcomes following related and HLA-mismatched HSCT in children with MIOP who stand to benefit from rapid grafting following diagnosis. Schulz et al. 10 reported relatively favorable overall outcomes with this donor strategy. All patients in the series received PBSC grafts after passive and ex vivo T-cell depletion was achieved by CD34 + cell selection. Still, of the four children with MIOP undergoing first transplant from a 41 HLA Ag-mismatched donor, only two survived. One patient died from graft failure; the other died from regimen-related toxicity.
The Haplo-PTCy strategy carries several theoretical advantages over other haploidentical approaches that use ex vivo and indiscriminate T-cell depletion. First, as Haplo-PTCy uses widely available and common pharmacologic agents, it is likely both less expensive and more accessible to the global MIOP population. Second, through preferential depletion of proliferating T cells, PTCy appears to provide for faster immune reconstitution. 11, 12 As numerous reports now chronicle the success of Haplo-PTCy following the non-myeloablative conditioning in malignant and hematologic disorders, we hypothesized that this HLA-disparate allograft source might allow for less intense pharmacologic conditioning in children with MIOP, with reliance on large CD34 + and CD3 + parental cell doses to increase the likelihood of engraftment.
The failure of the regimen reported herein to achieve engrafted survival in two of the three infants with MIOP could stem from several causes. First, it is possible that the timing (proximal to allograft infusion) and dosing of thymoglobulin are not optimal for balancing maximal recipient immune depletion with minimal interference of donor-derived T lymphocytes. 13 It is important to note that for patient 2, a measureable recipient T-cell population was quantifiable at day +42 (absolute CD3 + count of 106 cells/μL; 100% recipient DNA). Similarly, for patient 3, a measurable recipient peripheral blood total absolute lymphocyte count (600/μL) was present prior to autologous graft rescue. As we did not assess thymoglobulin levels prior to allograft infusion, it is difficult to know if excessive free Ab contributed to the depletion of donor T cells in these two patients; in this respect, it is noteworthy that the sole patient to engraft received the largest T-cell dose with allografting.
It is also likely that the total busulfan exposure targeted in this regimen (40 mg × h × L − 1 , or 10 500 μmol × min × L − 1 ) is insufficient for consistent myeloablation in a disease characterized by significant extramedullary hematopoiesis. In support of this, both patients 2 and 3 demonstrated residual recipient peripheral blood myeloid cells (CD15 + ) from as early as day +21 (even though patient 3 exhibited overall minimal active myelopoiesis).
With this report we do not suggest that the Haplo-PTCy strategy is not a viable one for the MIOP population. Rather, we propose that modifications to the preparative regimen herein are strongly advisable. In fact, as the Haplo-PTCy platform consistently demonstrates very low rates of severe acute GvHD for patients with hematologic malignancies (even with regimens that do not contain thymoglobulin or other 'serotherapy'), it may be advisable to administer such agents at a more distal time point relative to allograft infusion for MIOP to optimize recipient immune depletion, whereas sparing the donor T-cell population that may be important for engraftment. 4 In addition, a higher totalexposure busulfan conditioning regimen (90 mg × h × L − 1 , or 21 500 μmol × min × L − 1 ) was reported to be successful in a relatively large pediatric population undergoing umbilical cord blood transplantation. This approach in a number of children with nonmalignant transplant indications provided excellent engraftment and low regimen-related toxicity.
14 It remains difficult to know how high-exposure busulfan might be tolerated in MIOP. Agents such as prophylactic defibrotide could be a useful adjunctive strategy to minimize hepatic injury. 8 In summary, Haplo-PTCy following reduced-intensity busulfan, fludarabine and thymoglobulin conditioning for three children with MIOP failed to provide consistent engrafted survival. Although the Haplo-PTCy platform may ultimately prove ideal for this patient population, considerations to modify the intensity and the timing of agents in this reported regimen are warranted. Figure 1 . The regimen used for three children with MIOP undergoing Haplo-PTCy transplantation comprised ATG = thymoglobulin, 2.5 mg/kg IV daily (10 mg/kg total); BU (busulfan), IV once daily, first dose determined by weight and age nomogram; 15 (total busulfan exposure target of 40 mg × h × L − 1 or 10 500 μmol × min × L − 1 ); FLU (fludarabine), 40 mg/m 2 IV daily (160 mg/m 2 total); PBSCT = G-CSF mobilized, T-cell replete, paternal PBSC graft; CY = cyclophosphamide, 50 mg/kg IV daily (100 mg/kg total); CSA = cyclosporine A; MMF (mycophenolate mofetil); GM-CSF = sargramostim, 250 μg/m 2 daily through neutrophilic recovery; G-CSF = filgrastim, 10 μg/kg subcutaneously daily.
